Corporate Presentation February 2023 NASDAQ: OTLK outlooktherapeutics.com Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for bevacizumab in ophthalmology 2 Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. (“Outlook Therapeutics” or the “Company”) based on management’s current expectations, which are subject to known and unknown uncertainties and risks. Words such as “anticipate,” “believe,” “estimate,” “expec ...